Xponance Inc. Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Xponance Inc. lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,498 shares of the life sciences company’s stock after purchasing an additional 1,556 shares during the quarter. Xponance Inc.’s holdings in Illumina were worth $3,541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ILMN. WCM Investment Management LLC grew its stake in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares during the period. ARK Investment Management LLC bought a new position in shares of Illumina during the 4th quarter valued at approximately $91,714,000. Massachusetts Financial Services Co. MA grew its stake in shares of Illumina by 148.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after acquiring an additional 631,294 shares during the period. Janus Henderson Group PLC grew its stake in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the period. Finally, Nikko Asset Management Americas Inc. bought a new position in shares of Illumina during the 4th quarter valued at approximately $65,813,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Canaccord Genuity Group cut their price objective on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, March 11th. Piper Sandler boosted their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Royal Bank of Canada lowered their price target on Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Stephens reissued an “overweight” rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Stock Down 0.2 %

Shares of ILMN opened at $84.79 on Friday. The business’s 50 day simple moving average is $109.19 and its 200-day simple moving average is $128.58. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The stock has a market capitalization of $13.43 billion, a price-to-earnings ratio of -11.04, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.